PHILADELPHIA, PA— Dapagliflozin given to acute MI patients with either impaired LV function or Q-wave MI in the DAPA-MI trial significantly improved cardiometabolic outcomes, despite the trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results